By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.

SGLT2i tool developed after evidence review

By Editor
23rd July 2018
DKA, Good practice Pharmaceutical Research Type 2 diabetes

A benefit and risk tool has been developed for the use of SGLT2 inhibitors following a review of available evidence.

The quick reference guide aims to provide clarity regarding common areas of confusion in clinical practice associated with risk of lower limb amputations and bone fractures, late and early use of SGLT2i treatments within the type 2 diabetes pathway and risk of diabetic ketoacidosis (DKA).

It was developed by the Improving Diabetes Steering Committee, a group of leading diabetes specialists in the UK, and was published today in their first joint paper in Diabetes Therapy titled ‘SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice’.

Helping to improve education in diabetes management is key to improving outcomes in the UK. Professor John Wilding, one of the co-authors of the paper

The committee came together to address priorities in improving the management of type 2 diabetes, focusing on the place of the SGLT2i class of medicines, in the context of the current UK treatment pathway.

The published paper is a balanced review of the current evidence around the use of SGLT2is and addresses conflicting information that healthcare professionals have been given over time about the SGLT2i class and the appropriate place of these therapies within the type 2 diabetes treatment pathway.

In developing the paper, the committee wanted to address these issues by summarising current data and providing time-poor clinicians with clear, evidence-based guidance to help build confidence and understanding of this class of medications. With this in mind, the committee also included the benefit and risk tool, which summarises the information in the review, to support primary care clinicians in identifying the people most likely to benefit from SGLT2i treatments, as well as situations where caution may be required.

Professor John Wilding, who leads diabetes and obesity research at the University of Liverpool, and is one of the co-authors of the paper said: “Helping to improve education in diabetes management is key to improving outcomes in the UK. As a committee, our focus was on providing balanced, accurate and evidence-based guidance to help clinicians identify those patients who would benefit most from the SGLT2i class of medicines.”

Dr Kevin Fernando, a GP partner at North Berwick Health Centre, near Edinburgh, and co-author of the paper, added: “Managing patients with type 2 diabetes is complex and can be challenging, particularly for clinicians working in primary care who are faced with many competing clinical priorities. We felt it was important to help provide every day, usable tools that will help healthcare professionals ensure their patients receive optimal care for their type 2 diabetes.”

To access the paper and benefit and risk tool, click here.

Comments (0)

Register an account or login to comment